|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
GB8909916D0
(en)
|
1989-04-29 |
1989-06-14 |
Delta Biotechnology Ltd |
Polypeptides
|
|
EP1243652A3
(en)
|
1991-09-20 |
2003-03-26 |
Amgen Inc., |
Glial derived neurotrophic factor
|
|
US20040175795A1
(en)
|
1991-09-20 |
2004-09-09 |
Amgen Inc. |
Glial derived neurotrophic factor
|
|
US5733875A
(en)
|
1994-11-15 |
1998-03-31 |
Amgen Inc. |
Methods of using GDNF as a neuroprotective agent
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
AU5576796A
(en)
|
1995-04-26 |
1996-11-18 |
Regeneron Pharmaceuticals, Inc. |
Methods of using neurotrophic factors to enhance neuronal gr afts
|
|
US6184200B1
(en)
|
1995-09-28 |
2001-02-06 |
Amgen Inc. |
Truncated glial cell line-derived neurotrophic factor
|
|
US5731284A
(en)
|
1995-09-28 |
1998-03-24 |
Amgen Inc. |
Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
|
|
AU1121997A
(en)
|
1995-11-29 |
1997-06-19 |
Amgen, Inc. |
Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
|
|
US5641750A
(en)
|
1995-11-29 |
1997-06-24 |
Amgen Inc. |
Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US5641749A
(en)
|
1995-11-29 |
1997-06-24 |
Amgen Inc. |
Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
|
|
US5929041A
(en)
|
1996-02-23 |
1999-07-27 |
Amgen Inc. |
Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
|
|
US5837681A
(en)
|
1996-02-23 |
1998-11-17 |
Amgen Inc. |
Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US5741778A
(en)
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US6455277B1
(en)
|
1996-04-22 |
2002-09-24 |
Amgen Inc. |
Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
|
|
US7138251B1
(en)
|
1996-04-22 |
2006-11-21 |
Amgen Inc. |
Polynucleotides encoding a neurotrophic factor receptor
|
|
AU7165998A
(en)
|
1997-05-30 |
1998-12-30 |
Amgen, Inc. |
Neurotrophic factor receptors
|
|
AU2354600A
(en)
|
1998-12-09 |
2000-06-26 |
Amgen, Inc. |
Grnf4 a neurotrophic factor
|
|
EP1240337B1
(en)
*
|
1999-12-24 |
2006-08-23 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
|
WO2005003296A2
(en)
*
|
2003-01-22 |
2005-01-13 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
AU2003256613A1
(en)
|
2002-07-19 |
2004-02-09 |
Amgen Inc. |
Protein conjugates with a water-soluble biocompatible, biogradable polymer
|
|
US8946151B2
(en)
|
2003-02-24 |
2015-02-03 |
Northern Bristol N.H.S. Trust Frenchay Hospital |
Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
|
|
TW200607523A
(en)
*
|
2004-06-01 |
2006-03-01 |
Domantis Ltd |
Drug compositions, fusions and conjugates
|
|
WO2006031994A2
(en)
|
2004-09-14 |
2006-03-23 |
Xencor, Inc. |
Monomeric immunoglobulin fc domains
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
WO2008022349A2
(en)
*
|
2006-08-18 |
2008-02-21 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
|
CA2687377C
(en)
*
|
2007-05-30 |
2013-05-14 |
Genexine Co., Ltd. |
Immunoglobulin fusion proteins
|
|
US20110045007A1
(en)
*
|
2007-05-31 |
2011-02-24 |
Genmab A/S |
Fusion or linked proteins with extended half life
|
|
WO2009070597A2
(en)
*
|
2007-11-26 |
2009-06-04 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of gdnf to the cns
|
|
BRPI1012971A2
(pt)
|
2009-06-11 |
2018-01-16 |
Angiochem Inc |
proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central
|
|
CA2781539C
(en)
|
2009-11-23 |
2021-07-20 |
Amgen Inc. |
Monomeric antibody fc
|
|
SMT201700025T1
(it)
|
2011-04-13 |
2017-03-08 |
Bristol Myers Squibb Co |
Proteine di fusione ad fc comprendenti nuovi raccordi o arrangiamenti
|
|
US20160296632A1
(en)
*
|
2013-11-13 |
2016-10-13 |
Aequus Biopharma, Inc. |
Engineered glycoproteins and uses thereof
|
|
EA034886B1
(ru)
|
2014-03-20 |
2020-04-02 |
Бристол-Майерс Сквибб Компани |
Связывающие сывороточный альбумин домены фибронектина iii типа
|
|
CA3043179A1
(en)
|
2016-11-10 |
2018-05-17 |
Keros Therapeutics, Inc. |
Gdnf fusion polypeptides and methods of use thereof
|